Yale Cancer Center | Strategic Alliance Partners

Daniel P. Petrylak, MD, sheds light on the emerging roles of both immunotherapy and targeted agents in the treatment of patients with bladder cancer.

Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.

Erin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses what impact the advancements with molecular testing have had on the identification of genetic abnormalities in patients with breast cancer.

Marcus Bosenberg, MD, PhD, associate professor of dermatology and pathology, Yale University, discusses mouse models for testing immunotherapies.

PARP inhibitors still have a place in the treatment paradigm of triple-negative breast cancer, but the role of these agents are significantly evolving.

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer with brain metastases to determine the best option for treatment.

Pooled data from ten universities finds added benefit from radiation boost among patients with negative margins following breast-conserving surgery.

In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.

The association between provider case volume and outcomes has long been suggested in cancer care.

Brigid Killelea, MD, MPH, FACS, associate professor of surgery (oncology), Yale Cancer Center, discusses the potential of nipple-sparing mastectomy for women who undergo surgery for breast cancer.

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, explains some of the most discussed topics in breast cancer. Chagpar was recently the chair at the State of the Science Summit on Breast Cancer held Sept. 15.

Barbara A. Burtness, MD, discussed the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

Malini Harigopal, MD, associate professor of Pathology, interim director of Breast Pathology, Yale School of Medicine, Yale Cancer Center, discusses the advancements in the pathology of breast cancer.

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.

Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved.

Daniel P. Petrylak, MD, professor of Medicine, Yale Cancer Center, discusses his vision for radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how it integrates with chemotherapy and other agents for treatment of this patient population.

Vincent T. DeVita Jr, MD, discusses his insights into the operations of the FDA and the National Cancer Institute will hold a special appeal for oncology specialists and healthcare providers in his book, "The Death of Cancer."

Mario Sznol, MD, discusses the current state of immunotherapy in renal cell carcinoma, emerging agents and combinations in the field, and the challenges that arise with finding biomarkers.

Madhav Dhodapkar, MBBS, discusses research showing that nflammation and chronic stimulation of the immune system by lipids may trigger multiple myeloma in approximately one-third of all cases.

Yale Cancer Center researchers have identified a link between lipids and a third of all myelomas, a type of cancer affecting plasma cells.

A team of researchers from Yale School of Public Health and Yale Cancer Center recently published a study in the Journal of Cancer Survivorship that addresses the needs of cancer survivors who are at least nine years beyond an initial diagnosis.

Substantial evidence exists that a subset of squamous cell cancers of the head and neck display phenotypic changes that predict activity for immune checkpoint inhibitors.

Anees B. Chagpar, MD, shares her thoughts on the final US Preventive Services Task Force guidelines and how they change the focus of breast cancer screening.

Patricia M. LoRusso, D.O. was among a group of 15 top cancer researchers and physician-scientists who met in Washington with aides to Vice President Joe Biden on Jan. 8 to discuss his “moonshot” program to advance cancer treatment.

The US Preventive Services Task Force has issued final guidelines that stand by its recommendation that women at average risk of breast cancer should not start routine screenings until they reach age 50 years and that they should then undergo testing every 2 years.

Choosing a research mentor is one of the most important steps when beginning a successful academic research career.

Treatment with pembrolizumab reduced the risk of death by 29% compared with docetaxel for patients with PD-L1-positive non–small cell lung cancer.

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

A Yale Cancer Center study published recently in the Journal of Clinical Oncology found that among minority women treated with early chemotherapy, black women fare worse than the other groups.

Marianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses immune-mediated adverse events in lung cancer.